In collaboration with colleagues at Baylor University (Kevin Pinney and Mary Lynn Trawick) and the Simmons Comprehensive Cancer Center (Hans Hammers and Payal Kapur), the Mason lab has been developing novel vascular disrupting agents. Notably, the dihyrdonaphthalene phosphate pro-drug OXi6197 binds tubulin causing selective disaggregation of cytoskeletons in endothelial cells in tumors. Rapid vascular shutdown was observed in orthotopic breast xenograft and syngeneic kidney tumors growing in mice, and repeat dosing led to significant tumor growth delay, as presented on the attached poster. The work is now featured in the published manuscript “Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment“ Li Liu, Regan Schuetze, J. L. Gerberich, R. Lopez, S. O. Odutola, R. P. Tanpure, A. K. Charlton-Sevcik, J. K. Tidmore, E A.-S. Taylor, P. Kapur, H. Hammers, M L. Trawick, K. G. Pinney, and R. P. Mason,Cancers 14(17): 2022,
In a second study led by post doc Hashini Wanniarachchi multispectral optoacoustic tomography and BLI were used to examine the effect of the indole phosphate pro-drug Oxi8007 in terms of vascular disruption of orthotopic RENCA kidney tumors (see attached)
